Shiyao Group (01093): Phase Ib clinical trial of jmt206 injection for weight management in overweight or obese adult patients officially launched at the first research center in China

Zhitongcaijing · 2d ago

Zhitong Finance App News, Shiyao Group (01093) announced that the Phase Ib clinical trial (JMT206-003) of the jMT206 injection developed by the group for weight management in overweight or obese adult patients has been officially launched at the first research center in China.

This product is registered as a therapeutic biological product category 1. It is a recombinant all-human antiactivin receptor type IIA (“Actr-IIIb”) monoclonal antibody. It can specifically bind to Actr-IIa and Actr-IIIb on the surface of target cell membranes to block activation of Actr-IIa and Actr-IIIb signaling pathways, thereby promoting muscle mass gain and weight loss. Preclinical studies have shown that the product has shown good muscle gain and fat loss effects, as well as safety and tolerability.

In November 2025, the Group obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration of the People's Republic of China for the indication of the use of this product for overweight or obesity, and commenced phase I clinical trials after approval. Phase I clinical trial data initially verified the safety, pharmacokinetics, and pharmacokinetic characteristics of the product in healthy participants.

The Phase Ib clinical trial initiated this time is a randomized, double-blind, placebo-controlled clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacokinetic characteristics of this product as a single drug or a combination of simeglutide injections and multiple subcutaneous injections in obese participants. Currently, the recruitment and screening of participants for this clinical trial is being actively promoted.